Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) Stock Has Average Price Target of $6.83

Shares of Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) have earned an average recommendation of “Moderate Buy” from the five brokerages that are currently covering the stock, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation, one has given a hold recommendation, two have given a buy recommendation and one has issued a strong buy recommendation on the company. The average 1 year price target among analysts that have issued ratings on the stock in the last year is $7.38.

A number of brokerages recently commented on MRVI. Weiss Ratings reissued a “sell (d-)” rating on shares of Maravai LifeSciences in a research note on Wednesday, August 26th. UBS Group lifted their price objective on Maravai LifeSciences from $2.50 to $8.00 and gave the stock a “neutral” rating in a research note on Wednesday, September 9th. Wall Street Zen cut Maravai LifeSciences from a “buy” rating to a “hold” rating in a report on Saturday, August 29th. Wells Fargo & Company upped their price objective on Maravai LifeSciences from $5.50 to $6.50 and gave the stock an “overweight” rating in a report on Friday, August 7th. Finally, TD Cowen started coverage on Maravai LifeSciences in a research report on Monday, October 5th. They set a “buy” rating and a $9.00 target price for the company.

Institutional Investors Weigh In On Maravai LifeSciences

Hedge funds have recently bought and sold shares of the business. General American Investors Co. Inc. increased its holdings in shares of Maravai LifeSciences by 1,062.2% in the 4th quarter. General American Investors Co. Inc. now owns 1,585,316 shares of the company’s stock worth $5,152,000 after buying an additional 1,448,907 shares during the last quarter. Dimensional Fund Advisors LP lifted its holdings in shares of Maravai LifeSciences by 64.8% in the 1st quarter. Dimensional Fund Advisors LP now owns 1,418,597 shares of the company’s stock valued at $4,015,000 after acquiring an additional 558,050 shares during the last quarter. Eversept Partners LP lifted its holdings in shares of Maravai LifeSciences by 147.2% in the 4th quarter. Eversept Partners LP now owns 718,582 shares of the company’s stock valued at $2,335,000 after acquiring an additional 427,909 shares during the last quarter. Bank of New York Mellon Corp purchased a new position in Maravai LifeSciences in the second quarter worth about $2,230,000. Finally, Capricorn Fund Managers Ltd purchased a new position in Maravai LifeSciences in the first quarter worth about $961,000. Hedge funds and other institutional investors own 50.25% of the company’s stock.

Maravai LifeSciences Price Performance

MRVI opened at $7.44 on Monday. The company has a market capitalization of $1.93 billion, a PE ratio of -14.31 and a beta of 0.54. The firm has a 50-day simple moving average of $7.18 and a two-hundred day simple moving average of $5.64. The company has a quick ratio of 2.98, a current ratio of 4.05 and a debt-to-equity ratio of 0.49. Maravai LifeSciences has a 52 week low of $2.55 and a 52 week high of $9.42.

Maravai LifeSciences (NASDAQ:MRVI) last issued its earnings results on Thursday, August 6th. The company reported ($0.02) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.04) by $0.02. The firm had revenue of $51.44 million for the quarter, compared to analysts’ expectations of $48.67 million. Maravai LifeSciences had a negative return on equity of 15.70% and a negative net margin of 37.07%. Analysts forecast that Maravai LifeSciences will post -0.20 earnings per share for the current fiscal year.

About Maravai LifeSciences

Maravai LifeSciences Holdings, Inc is a life sciences company that provides products and services used in the development and manufacture of biopharmaceuticals, vaccines, diagnostics and other advanced biological products. The company serves research, pharmaceutical, biotechnology and healthcare customers involved in nucleic acid production, biologics development and quality testing.

Maravai’s Nucleic Acid Production segment, which includes TriLink BioTechnologies, supplies specialized messenger RNA and other nucleic acid products, raw materials and related manufacturing services.